Stallergènes News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.09.15	Combination of STALLERGENES and Greer Laboratories: Ares Allergy Holdings Plc Has Secured AMF Approval of Its Prospectus for Listing Its Shares on Euronext Paris (Businesswire)
31.08.15	Combination of Stallergenes and Greer Laboratories: End of the Liquidity Contract for Stallergenes Shares (Businesswire)
22.07.15	STALLERGENES : Strong Revenue Growth in H1 2015 (up 8.7%) Exceeding Targets (Businesswire)
21.07.15	Project to Combine Stallergenes and Greer Laboratories: The New Board of Ares Allergy Appoints Fereydoun Firouz Chairman and CEO (Businesswire)
26.06.15	STALLERGENES Shareholders Approve the Project to Combine the Activities of the Group and GREER Laboratories (Businesswire)
11.06.15	STALLERGENES : Procedures for Availability and Consultation of Information for the General Meeting of 26 June 2015 (Businesswire)
28.05.15	STALLERGENES: Procedures for Availability and Consultation of Preparatory Documents for the General Meeting of 26 June 2015 (Businesswire)
28.05.15	Project to Combine STALLERGENES and Greer Laboratories: Information Document Available as of Today (Businesswire)
20.05.15	Project to Combine STALLERGENES and Greer Laboratories: Draft Merger Agreement and Reports from Court-Appointed Expert Ledouble Now Available (Businesswire)
13.05.15	Project to Combine STALLERGENES and GREER Laboratories (Businesswire)
13.05.15	Project to Combine Stallergenes and Greer Laboratories (Businesswire)
21.04.15	STALLERGENES: Strong Sales Growth in Q1 2015 (up 7.5%) Exceeding Targets (Businesswire)
15.04.15	Board of Directors of STALLERGENES: Assessment of the Proposed Combination of STALLERGENES and GREER LABORATORIES Has Begun (Businesswire)
30.03.15	STALLERGENES ANNOUNCES THE APPROVAL IN JAPAN OF STG320, THE FIRST SUBLINGUAL IMMUNOTHERAPY TABLET FOR THE TREATMENT OF HOUSE DUST MITE ALLERGY (Businesswire)
26.03.15	Board of Directors of STALLERGENES: Update on the Project to Combine STALLERGENES and GREER Laboratories (Businesswire)
03.03.15	Project to Combine STALLERGENES and GREER LABORATORIES Submitted to the Board of the Company (Businesswire)
03.03.15	STALLERGENES: 2.5% Growth in Net Sales (Businesswire)
20.11.14	STALLERGENES and ActoGeniX to Develop an Innovative New Class of Oral Allergy Treatments (Businesswire)
23.10.14	STALLERGENES Sales Reach €45.7 Million in Q3 2014 (Businesswire)
24.07.14	Stallergenes: Half-Year Revenues and Results (Businesswire)
22.07.14	STALLERGENES baut lateinamerikanische Präsenz mit der Übernahme von ALERGO PHARMA S.R.L. in Argentinien aus (Businesswire)
21.07.14	STALLERGENES Expands Latin American Presence with Acquisition of ALERGO PHARMA S.R.L. in Argentina (Businesswire)
21.07.14	STALLERGENES Expands Latin American Presence with Acquisition of ALERGO PHARMA S.R.L. in Argentina (Businesswire)
24.04.14	STALLERGENES Posts Sales Growth of 1.5% in Q1 2014, Continues International Expansion (up 21.2%) and is Ready to Launch ORALAIR® in the U.S with Greer (Businesswire)
02.04.14	STALLERGENES meldet FDA-Zulassung von ORALAIR®, der ersten sublingualen Immuntherapietablette zur Behandlung von Graspollenallergien (Businesswire)
02.04.14	STALLERGENES Announces FDA Approval of ORALAIR®, the First Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy (Businesswire)
05.03.14	Appointment of Christian Chavy as Chief Executive Officer of Stallergenes (Businesswire)
05.03.14	Stallergenes Posts Revenue Growth of 3.5% in 2013 and Increases Its Profitability (EBITDA: €71.3 Million, up 2.8%) (Businesswire)
03.02.14	Stallergenes Reports Positive Results in the Phase II / III Clinical Trial of House Dust Mite Immunotherapy Tablets in Japan (Businesswire)
11.12.13	FDA Advisory Committee Supports Approval of STALLERGENES’ ORALAIR® for the Treatment of Grass Pollen Allergy (Businesswire)
02.12.13	STALLERGENES and ActoGeniX to Develop Together an Innovative New Class of Oral Treatments for Allergy (Businesswire)
31.10.13	GREER® Laboratories, Inc. and STALLERGENES Sign Exclusive Agreement for United States Commercialization Rights to Oralair® (Businesswire)
21.10.13	Stallergenes : Q3 Revenue Growth of 3.6%, Driven by Positive Performance of Sublingual Immunotherapy Treatments (Businesswire)
18.10.13	Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch Pollen (Businesswire)
25.07.13	Stallergenes : Half-Year Revenues and Results (Businesswire)
14.01.13	Stallergenes 2012 Sales Grew at 3.3% with Strong Growth in the International Business (28%) (Businesswire)
22.11.12	Stallergenes Launches Oralair® in France, the Only Immunotherapy Tablet with 5 Grass Pollen Tailored to the Epidemiology and Patients’ Expectations (Businesswire)
10.10.12	Stallergenes: Cumulative Sales Growth of 4.3% to End September (Businesswire)
11.09.12	STALLERGENES : 2012 FIRST HALF-YEAR RESULTS (Businesswire)
28.08.12	Stallergenes and Aerocrine Sign Exclusive Distribution Agreement for NIOX MINO®, an Innovative Device to Allow Better Diagnosis and Monitoring of Asthma (Businesswire)
12.07.12	Stallergenes: 1st Half-Year 2012: Sales up 6% (Businesswire)
13.06.12	Patrick Langlois Appointed Non Executive Chairman of the Board of Directors of Stallergenes (Businesswire)
30.05.12	Stallergenes Makes One Step Forward to the Launch of Oralair® in France (Businesswire)
21.05.12	Stallergenes Remains Committed to the Recognition of Innovative Pharmaceutical Companies and Has Joined G5 Health (Businesswire)
04.05.12	Stallergenes Announces Positive Clinical Results for Its House Dust Mites Immunotherapy Tablet (Businesswire)
12.04.12	Quarterly Information : Stallergenes Continues to Grow (Businesswire)
02.04.12	Stallergenes Has Identified Two Candidate Biomarkers of Early Efficacy of Allergen Immunotherapy (Businesswire)
21.03.12	Stallergenes Continues Its Strategic International Expansion with the Successfull Registration in Canada of Oralair™ Tablet for Grass Pollen (Businesswire)
19.03.12	Stallergenes: 2011 Financial Results (Businesswire)
12.01.12	Stallergenes: 2011 Sales up 9% Market Share Gains (Businesswire)
11.01.07	Best Buy, Clear Channel Gaming Auction Raises $470,000 for Toys for Teens (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’317.00	3.82 %	K V
ABB	50.46	1.98 %	K V
Holcim	89.34	1.43 %	K V
Roche Hldg G	268.00	1.36 %	K V
Sika	219.60	1.24 %	K V
Kuehne+Nagel Int	208.60	0.05 %	K V
Geberit	513.80	0.04 %	K V
Logitech Intl	79.64	-0.30 %	K V
Sonova Hldg	297.10	-0.30 %	K V
Zurich Insur Gr	549.80	-0.36 %	K V

Nachrichten zu Stallergènes S.A. (Stallergenes S.A.)

Aktien Top/Flop

Meistgelesene Nachrichten